Loading
UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
E2 ubiquitin-conjugating enzyme that accepts ubiquitin from the ubiquitin-activating enzyme E1 and transfers it to a E3 ubiquitin-protein ligase. In vitro catalyses 'Lys-11', as well as 'Lys-48'-linked polyubiquitination. Together with the E3 enzyme BRE1 (RNF20 and/or RNF40), plays a role in transcription regulation by catalysing the monoubiquitination of histone H2B at 'Lys-120' to form H2BK120ub1.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS.
In plain words · UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
E2 ubiquitin-conjugating enzyme that accepts ubiquitin from the ubiquitin-activating enzyme E1 and transfers it to a E3 ubiquitin-protein ligase. In vitro catalyses 'Lys-11', as well as 'Lys-48'-linked polyubiquitination.
No product in this corpus aims at UBE2A yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA UBE2A: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P49459; CIViC gene UBE2A; IntOGen UBE2A; Human Protein Atlas UBE2A tissue; Open Targets ENSG00000077721 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Koken M.H.M. et al, Proc. Natl. Acad. Sci. U.S.A, 1991, "Structural and functional conservation of two human homologs of the yeast DNA repair gene RAD6". Source.
Sources: HGNC HGNC:12472 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49459 (protein name, function text, keywords and locations (REST API)); CIViC gene UBE2A (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen UBE2A (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E2 ubiquitin-conjugating enzyme that accepts ubiquitin from the ubiquitin-activating enzyme E1 and transfers it to a E3 ubiquitin-protein ligase. In vitro catalyses 'Lys-11', as well as 'Lys-48'-linked polyubiquitination. Together with the E3 enzyme BRE1 (RNF20 and/or RNF40), plays a role in transcription regulation by catalysing the monoubiquitination of histone H2B at 'Lys-120' to form H2BK120ub1. H2BK120ub1 gives a specific tag for epigenetic transcriptional activation, elongation by RNA polymerase II, telomeric silencing, and is also a prerequisite for H3K4me and H3K79me formation. Involved in mitophagy by acting as a E2 ubiquitin-conjugating enzyme for PRKN. In association with the E3 enzyme UBR4, is involved in N-end rule-dependent protein degradation. Location: Late endosome; Lysosome (UniProt). Locus Xq24 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"UBE2A" OR ABSTRACT:"UBE2A" OR TITLE:"ubiquitin conjugating enzyme E2 A" OR ABSTRACT:"ubiquitin conjugating enzyme E2 A" OR TITLE:"Ubiquitin-conjugating enzyme E2 A" OR ABSTRACT:"Ubiquitin-conjugating enzyme E2 A" OR TITLE:"UBC2" OR ABSTRACT:"UBC2" OR TITLE:"HHR6A" OR ABSTRACT:"HHR6A" OR TITLE:"RAD6A" OR ABSTRACT:"RAD6A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about UBE2A, not a curated reading list.